Shenzhen Hepalink Pharmaceutical Group Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
1,926
- Stock Symbol
-
002399
- Investments
-
13
- Share Price
-
$1.58
- (As of Friday Closing)
Shenzhen Hepalink Pharmaceutical Group General Information
Description
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business, and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from USA and Europe.
Contact Information
Website
www.hepalink.comCorporate Office
- Number 21, Langshan Road, Songping Mountain
- Shenzhen, Guangdong Sheng 518057
- China
Corporate Office
- Number 21, Langshan Road, Songping Mountain
- Shenzhen, Guangdong Sheng 518057
- China
Shenzhen Hepalink Pharmaceutical Group Stock Performance
As of 16-May-2025, Shenzhen Hepalink Pharmaceutical Group’s stock price is $1.58. Its current market cap is $2.1B with 1.47B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.58 | $1.55 | $1.11 - $1.79 | $2.1B | 1.47B | 5.51M | $0.06 |
Shenzhen Hepalink Pharmaceutical Group Financials Summary
As of 31-Mar-2025, Shenzhen Hepalink Pharmaceutical Group has a trailing 12-month revenue of $736M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 2,174,664 | 2,124,692 | 2,671,146 | 2,862,384 |
| Revenue | 735,821 | 735,941 | 769,705 | 1,063,088 |
| EBITDA | 110,704 | 160,838 | (52,445) | 195,799 |
| Net Income | 89,976 | 90,132 | (110,710) | 108,014 |
| Total Assets | 2,415,513 | 2,375,793 | 2,709,056 | 3,017,123 |
| Total Debt | 494,674 | 485,583 | 784,755 | 936,893 |
Shenzhen Hepalink Pharmaceutical Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Shenzhen Hepalink Pharmaceutical Group Patents
Shenzhen Hepalink Pharmaceutical Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4273540-A1 | Method for detecting content of glycosaminoglycan carboxylated derivative in sample, and application thereof | Pending | 31-Dec-2020 | ||
| US-20240085383-A1 | Method for detecting content of glycosaminoglycan carboxylated derivative in sample, and application thereof | Pending | 31-Dec-2020 | ||
| JP-2024505364-A | Method and use thereof for detecting the content of carboxylated glycosaminoglycan derivatives in a sample | Active | 31-Dec-2020 | ||
| JP-7606000-B2 | Method for detecting the content of carboxylated glycosaminoglycan derivatives in a sample and use thereof - patents.com | Active | 31-Dec-2020 | ||
| EP-4273540-A4 | Method for detecting content of glycosaminoglycan carboxylated derivative in sample, and application thereof | Pending | 31-Dec-2020 | G01N30/7233 |
Shenzhen Hepalink Pharmaceutical Group Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Shenzhen Hepalink Pharmaceutical Group Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Shenzhen Hepalink Pharmaceutical Group Investments & Acquisitions (13)
Shenzhen Hepalink Pharmaceutical Group’s most recent deal was a PIPE with Resverlogix for . The deal was made on 14-Aug-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Resverlogix | 14-Aug-2020 | PIPE | Pharmaceuticals | ||
| Resverlogix | 01-Apr-2019 | PIPE | Pharmaceuticals | ||
| Shenzhen Arimab Biopharmaceuticals | 27-Feb-2018 | Joint Venture | Other Healthcare Services | ||
| Resverlogix | 04-Dec-2017 | PIPE | Pharmaceuticals | ||
| Resverlogix | 20-Jun-2017 | Public Investment 2nd Offering | Pharmaceuticals |
Shenzhen Hepalink Pharmaceutical Group ESG
Risk Overview
Risk Rating
Updated February, 15, 2025
41.2 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,631
Rank
Percentile
Pharmaceuticals
Industry
of 843
Rank
Percentile
Pharmaceuticals
Subindustry
of 419
Rank
Percentile
Shenzhen Hepalink Pharmaceutical Group Exits (5)
Shenzhen Hepalink Pharmaceutical Group’s most recent exit was on 24-Nov-2016 from Kymab. The exit was categorized as with 6 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Kymab | 24-Nov-2016 | Completed |
|
||
| HighTide Therapeutics | 27-Jul-2016 | Completed |
|
||
| Aridis Pharmaceuticals | 01-Aug-2015 | Completed |
|
||
| Liminal Biosciences | 08-Jan-2013 | Completed |
|
||
| Cantex Pharmaceuticals | 04-Aug-2010 | Later Stage VC | Completed |
|
Shenzhen Hepalink Pharmaceutical Group Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Hepalink USA | 2013 | ||
| HighTide Therapeutics | Shenzhen, China | 2011 | |
| Scientific Protein Laboratories | Waunakee, WI | 1976 |
Shenzhen Hepalink Pharmaceutical Group FAQs
-
When was Shenzhen Hepalink Pharmaceutical Group founded?
Shenzhen Hepalink Pharmaceutical Group was founded in 1998.
-
Where is Shenzhen Hepalink Pharmaceutical Group headquartered?
Shenzhen Hepalink Pharmaceutical Group is headquartered in Shenzhen, China.
-
What is the size of Shenzhen Hepalink Pharmaceutical Group?
Shenzhen Hepalink Pharmaceutical Group has 1,926 total employees.
-
What industry is Shenzhen Hepalink Pharmaceutical Group in?
Shenzhen Hepalink Pharmaceutical Group’s primary industry is Pharmaceuticals.
-
Is Shenzhen Hepalink Pharmaceutical Group a private or public company?
Shenzhen Hepalink Pharmaceutical Group is a Public company.
-
What is Shenzhen Hepalink Pharmaceutical Group’s stock symbol?
The ticker symbol for Shenzhen Hepalink Pharmaceutical Group is 002399.
-
What is the current stock price of Shenzhen Hepalink Pharmaceutical Group?
As of 16-May-2025 the stock price of Shenzhen Hepalink Pharmaceutical Group is $1.58.
-
What is the current market cap of Shenzhen Hepalink Pharmaceutical Group?
The current market capitalization of Shenzhen Hepalink Pharmaceutical Group is $2.1B.
-
What is Shenzhen Hepalink Pharmaceutical Group’s current revenue?
The trailing twelve month revenue for Shenzhen Hepalink Pharmaceutical Group is $736M.
-
What is Shenzhen Hepalink Pharmaceutical Group’s annual earnings per share (EPS)?
Shenzhen Hepalink Pharmaceutical Group’s EPS for 12 months was $0.06.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
